Characteristics, phenotypes, mechanisms and management of severe asthma

Kian Fan Chung1,2, Piers Dixey1,2, Hisham Abubakar-Waziri1,2, Pankaj Bhavsar1,2, Pujan H. Patel1,2, Sujuan Guo3, Yang Ji3

1National Heart & Lung Institute, Imperial College London, London SW3 6LY, UK; 2Royal Brompton & Harefield NHS Hospitals, London, UK; 3Department of Respiratory Medicine, University of Hong Kong Shenzhen Hospital, Shenzhen, Guangdong 518053, China.

Abstract
Severe asthma is “asthma which requires treatment with high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming ‘uncontrolled’ or which remains ‘uncontrolled’ despite this therapy.” The state of control was defined by symptoms, exacerbations and the degree of airflow obstruction. Therefore, for the diagnosis of severe asthma, it is important to have evidence for a diagnosis of asthma with an assessment of its severity, followed by a review of comorbidities, risk factors, triggers and an assessment of whether treatment is commensurate with severity, whether the prescribed treatments have been adhered to and whether inhaled therapy has been properly administered. Phenotyping of severe asthma has been introduced with the definition of a severe eosinophilic asthma phenotype characterized by recurrent exacerbations despite being on high dose ICS and sometimes oral corticosteroids, with a high blood eosinophil count and a raised level of nitric oxide in exhaled breath. This phenotype has been associated with a Type-2 (T2) inflammatory profile with expression of interleukin (IL)-4, IL-5, and IL-13. Molecular phenotyping has also revealed non-T2 inflammatory phenotypes such as Type-1 or Type-17 driven phenotypes. Antibody treatments targeted at the T2 targets such as anti-IL5, anti-IL5Rα, and anti-IL4Rx antibodies are now available for treating severe eosinophilic asthma, in addition to anti-immunoglobulin E antibody for severe allergic asthma. No targeted treatments are currently available for non-T2 inflammatory phenotypes. Long-term azithromycin and bronchial thermoplasty may be considered. The future lies with molecular phenotyping of the airway inflammatory process to refine asthma endotypes for precision medicine.

Keywords: Severe asthma; Biologic therapies; Eosinophils; Neutrophils; Corticosteroid insensitivity; Type 2-high inflammation

Introduction
Asthma is a global health problem. It has been defined as a heterogeneous disease characterized by airway inflammation usually presenting with a history of wheeze, shortness of breath, chest tightness, and cough that vary with time and in intensity, associated with variable airflow obstruction. It affects around 300 million people globally of all ages and ethnicities, with a death rate of ~230,000 people each year. In China, a recent survey of a representative population of asthma found a prevalence of 4.2% of asthma in adults aged 20 or above, representing 45.7 million Chinese.[1] Asthma is associated with a high degree of morbidity, part of which is represented by those suffering from asthma despite being treated with anti-asthma medication, although many patients with asthma remain undiagnosed or are not receiving adequate medication. The recent asthma survey in China found 15.5% of asthmatics reporting at least one emergency room visit and 7.2% experiencing at least one hospital admission in the past year. It is likely that this morbidity is accounted for by inadequate treatment of asthma because only 5% to 6% of asthmatics had been treated with inhaled corticosteroids (ICS), suggesting undertreatment.[1]

It is those asthma patients who experience uncontrolled asthma despite adequate therapy who are now labelled as suffering from severe asthma that represent an important economic burden to healthcare providers. The prevalence of severe asthma has been reported to be 3.6% amongst asthmatics attending a hospital clinic in the Netherlands[2] and 4% to 6% in a Swedish cohort.[3] In China, the incidence of severe asthma amongst asthmatics ranges from 3.4% to 8.3%. [4-6] In terms of death rates from asthma, between 2011 and 2015 in high income countries, these are reported to be the highest in UK, Australia and
US averaging three to five standardized deaths per million population, while those in lower income countries as high as 12 to 25 per million population in Mauritius, South Africa and Philippines (http://globalasthmareport.org/burden/mortality.php; checked on October 6, 2021). Data regarding China are sparse, but in 2004 to 2005, a standardized death rate of 24.5 per million population was reported.\cite{7} It is to be noted that many of these asthma death rates are preventable because of inadequate diagnosis and treatment, and therefore the death rate due to uncontrolled or severe asthma would be lower than that reported. However, it is clear that the costs for uncontrolled or severe asthma are higher than those for controlled asthma. In Europe, the direct costs through hospital care, medication and indirect costs from time out of work range from 309 Euros per patient for those with controlled disease to 2281 Euros for uncontrolled disease per patient.\cite{8} The costs of asthma in Europe are estimated to be 21 billion Euros for asthmatics aged between 16 and 54 years in 2014. In the United States, $56 billion is the estimated costs for asthma in 2015 (www.aafa.org/page/cost-of-asthma-on-society.aspx; checked on October 5, 2021).

The last 20 years of research into asthma has improved our understanding of the asthma with the recognition that far from being a single disease entity, asthma is a complex heterogenous disease that presents with several clinical phenotypes driven by a multiplicity of molecular mechanisms. This complexity of the severe asthma diathesis has become fully appreciated following the international agreement of a working definition of severe asthma that has in turn led the foundation towards an increased understanding of the underlying phenotypes and mechanisms. The clarification of the inflammatory processes such as the dominance of the Type-2 (T2) inflammation and the concomitant phenotyping into clinical and molecular phenotypes has contributed to improving the management of these patients.\cite{9} This has subsequently led to the successful introduction of monoclonal antibody therapies directed at various targets underlying T2 inflammation, an example of precision medicine applied to severe asthma.

In this review, we will start with the agreed definition of severe asthma and the clinical approach to the diagnosis and management of patients with severe asthma. In parallel, we will describe the clinical and molecular phenotypes of severe asthma and the underlying driving mechanisms of severe asthma that underpin these phenotypes. Finally, we will review the new treatments that have been introduced for severe asthma and summarize current on-going research towards more precision medicine for severe asthma.

**Defining Severe Asthma**

Prior to any consensus on the definition of severe asthma, there has been several terms used by clinicians to characterize these patients such as “brittle” asthma, corticosteroid-resistant asthma, difficult-to-control asthma, difficult-to-treat asthma, difficult chronic asthma, and life-threatening asthma which qualify the type of asthma presenting in a particular asthma patient. One of the first international definitions of the World Health Organization (WHO) Consultation on Severe Asthma defined severe asthma as “uncontrolled asthma which can result in risk of frequent severe exacerbations (or death) and/or adverse reactions to medications and/or chronic morbidity.”\cite{10} This definition encompassed three groups of asthmatics: (1) untreated severe asthma representing patients who cannot receive treatment for their asthma because they cannot afford the treatments or do not have access to such treatments, (2) difficult-to-treat severe asthma in patients who are treated for their asthma but are not responsive to the treatments for many reasons including not being adherent to treatments or not receiving the right treatments, and (3) treatment-resistant severe asthma where control is not achieved despite the highest level of recommended treatment and asthma for which control can be maintained only with the highest level of recommended treatment.

A later definition of severe asthma from a task force of the European Respiratory Society (ERS) and American Thoracic Society (ATS)\cite{11} focused on severe asthma being a treatment-resistant asthma after the patient has been treated effectively and all other cofounders, such as medication compliance and comorbidities have been addressed. The definition was: “When a diagnosis of asthma is confirmed and comorbidities have been addressed, severe asthma is defined as ‘asthma which requires treatment with high dose ICS plus a second controller (and/or systemic corticosteroids) to prevent it from becoming ‘uncontrolled’ despite this therapy.”\cite{12} Uncontrolled asthma was defined according to the presence of poor symptom control, frequent severe exacerbations, serious exacerbations and presence of airflow limitation.

**Diagnosing and Managing Severe Asthma**

The diagnosis of severe asthma will be made in clinical practice in patients with asthma who remain uncontrolled despite receiving asthma treatments, at which stage the patient may be qualified as having “difficult-to-control asthma.” Within this cohort of difficult-to-control asthma who are referred to secondary care, a proportion will ultimately receive a diagnosis of severe asthma. This should happen when there has been exclusion of any other diagnoses that could mimic asthma, when the right treatments have been provided according to current guidelines and when the patient has been shown to be adherent to treatment. This approach will ensure that the first two types of patients under the WHO classification (untreated and difficult-to-treat asthma) have been excluded and that we have a patient with severe asthma according to the ATS-ERS definition of severe asthma.

It has been recommended that patients are evaluated within an asthma specialist service by a physician who specializes in asthma with access to the services of a whole multidisciplinary team.\cite{13} The assessment in a multidisciplinary team environment allows the experienced clinician to ensure that the classical symptoms of asthma (fluctuating dyspnoea, wheezing, cough) are caused by
asthma rather than one of the many other conditions that can cause a similar medley of clinical symptoms.

A systematic assessment of the patient with difficult-to-treat asthma should be performed within a severe asthma service [Table 1]. First, confirmation of the diagnosis of asthma and its severity should be evaluated, a process that can take up to 3 to 6 months of evaluation in the clinic. Bronchodilator reversibility or assessing variability of airflow obstruction with a peak flow diary or, if possible, the measurement of bronchial hyperreactivity may be used to support the diagnosis of asthma. High resolution computed tomography (HRCT) of the lungs is not indicated in the routine management of asthma but it can be used to exclude alternative diagnoses or the existence of additional conditions or co-morbidities of the lung. These conditions include intra- or extra-thoracic airway obstruction, obliterative bronchiolitis, chronic obstructive pulmonary disease, congestive heart failure, hypersensitivity pneumonitis, hyper-eosinophilic syndromes, allergic bronchopulmonary aspergillosis and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Assessing the factors that may underlie symptoms or exacerbations such as poor adherence to treatments and improper inhaler technique, comorbidities, and assessment of risk factors and triggers must be made [Supplementary Table 1, http://links.lww.com/CM9/A939]. Anxiety and depression and socio-economic factors may also form the basis of uncontrolled asthma. Social and psychological or psychiatric support may also be provided. The prevalence of treatable pulmonary and non-pulmonary traits is higher in severe asthma compared to non-severe asthma. [13] Use of a systematic approach and attention to managing comorbidities can improve outcomes, quality of life, asthma control, reduce health care usage, and minimize the amount of oral corticosteroid (OCS) use.[14,15]

Addressing non-adherence to prescribed inhaled and oral therapies is important since it can exist in 30% to 70% of prescribed medication[16] in difficult-to-treat asthma, including the adherence to oral prednisolone therapy.[17,18] For oral prednisolone adherence based on prednisolone-cortisol assays, the adherence varied from 33% to 45% in two specialist asthma centers.[18,19] Non-adherence has been associated with poorer asthma outcomes, from worsening symptoms scores, increase in hospitalization, exacerbations rates, and mortality.[16] Unintentional non-adherence can usually be addressed by better education, once a daily inhaler preparations, and ensuring (where possible) that if multiple inhalers in use are of the same type used in the same manner. Intentional non-adherence is a complex problem requiring further evaluation of the reasons behind it and will require other members of the asthma multidisciplinary team to be involved.[20]

Assessment of the severity of asthma based on the definition of asthma control is necessary. Severity has been defined according to either poor symptom control, or presence of frequent severe exacerbations or serious exacerbations or presence of airflow limitation. [11] Those patients that do not meet these criteria, whose asthma control worsens when tapering corticosteroid dose, also meet the criteria of severe asthma. These criteria can predict future risks from asthma as well as side-effects of medications.

Finally, treatments need to be reviewed and optimized. Combination therapy of long-acting beta-agonist (LABA) with medium/high dose ICS should be established, with addition of leukotriene modifier and long-acting muscarinic antagonist (LAMA). Use of daily oral prednisolone can be considered but with the introduction of targeted antibody therapies for severe asthma, resort to the use of OCS therapy may be reduced.

Self-management education should be provided with incorporation of a personalized written or electronic asthma action plan. A review at 3 to 6 months should determine whether the patient has severe asthma, with the diagnosis confirmed if the asthma remains uncontrolled despite optimization of therapy. If the asthma remains well-controlled, stepping-down treatment can be considered, and if asthma symptoms or exacerbations occur on stepping down high dose treatment, then severe asthma can be diagnosed.

### Table 1: Systematic assessment of difficult-to-treat/severe therapy resistant asthma.

| Item | Contents |
|------|----------|
| 1    | Refer to an asthma specialized service |
| 2    | Confirmation of asthma diagnosis: Lung function variability; bronchial provocation test |
| 3    | Exclude other conditions masquerading as asthma |
| 4    | Assess severity of disease: Poor symptom control, airflow obstruction, frequent exacerbations, life-threatening severe exacerbations |
| 5    | Check inhalation technique and adherence to treatments |
| 6    | Optimization of treatment according to national guidelines |
| 7    | Assess adherence to therapy |
| 8    | Adaptation and using self-management plans |
| 9    | Identification and avoidance of trigger factors |
| 10   | Assessment and management of comorbidities |
| 11   | Phenotyping according to clinical-physiological-inflammatoy parameters |
| 12   | Individualization of management plan |

### Risk Factors and Co-morbidities of Severe Asthma

Severe asthma phenotypes have been associated with genetic factors, age of asthma onset, disease duration, exacerbations, rhinosinusitis, and inflammatory characteristics.[21-24] Early childhood-onset severe asthma is characterized by allergic sensitization and a strong family history of asthma.[25,26] On the other hand, late-onset severe asthma is often associated with female gender and reduced lung function, persistent eosinophilic inflammation, nasal polyps and sinusitis, and aspirin sensitivity. [27-29]

Obesity is associated with childhood and adult-onset severe asthma, but its impact may differ by age at onset.
and the degree of allergic inflammation. Tobacco smoke and environmental air pollution have been considered as risk factors for more severe asthma. Cigarette smoking, exposure to air pollution and obesity have been linked to corticosteroid insensitivity, also present in severe asthma. Exacerbations in severe asthma are more frequent in those with comorbidities such as rhinosinusitis, gastro-oesophageal reflux disease, recurrent respiratory infections and obstructive sleep apnoea. Sensitization to the fungus, Aspergillus fumigatus, has also been linked to severe asthma development in adults.

Patients with severe asthma face the risks of lung function decline, recurrent exacerbations, corticosteroid-induced side effects and mortality, being greater in those with uncontrolled asthma as compared to those with controlled asthma. Future risk of exacerbations can be predicted from a history of exacerbations, in addition to other factors including smoking history, poor lung function, nasal polyps, obesity, and co-morbid depression. Loss of lung function in severe asthma has been associated with exacerbation rate, OCS usage, and age. Higher mortality has been associated with poor asthma control and presence of severe airflow obstruction. Severe asthma patients taking OCSs had more comorbidities that may be related to systemic corticosteroid exposure such as T2 diabetes, obesity, osteoporosis, hypertension, cataracts, and dyspeptic symptoms than those with milder asthma.

HRCT scan can also be used to denote future risks. The presence of air trapping on HRCT has been associated with asthma-related hospitalizations, intensive care unit visits, duration of asthma, airway neutrophilia, and airflow obstruction. Mucus plugging is another recognized feature of acute severe asthma and fatal asthma. Using a quantified mucus plugging scoring system, 67% of asthmatics with forced expiratory volume in one second (FEV1) of less than 60% predicted had plugs present in four or more lung segments.

**Long-term OCS therapy**

The co-morbidities that are associated with long-term OCS therapy need to be addressed by monitoring bone densitometry and treating reduced bone density appropriately as well as monitoring for metabolic sequelae of OCS use, such as non-alcoholic fatty liver disease. With the advent of monoclonal antibodies, or biologic therapies, the reliance on long-term OCS for the treatment of severe asthmatics has been reduced. This could occur with the early administration of such biologic therapies prior to considering the use of OCS therapy. In addition, with establishment of biologic therapies particularly anti-interleukin (IL) 5, anti-IL5Rα and anti-IL4Rα antibodies, the dose of OCS can be reduced and sometimes discontinued.

Corticosteroid-insensitive patients continue to experience side-effects from OCS therapy Use of sputum eosinophil counts which has been recommended by the ERS-ATS guidelines may help toward adjusting to the lowest dose of OCS needed. Low levels of sputum or blood eosinophil counts indicate a non-eosinophilic phenotype that is likely to be less responsive to OCS therapy, and therefore corticosteroids can be down-titrated. On the other hand, the blood eosinophil count may increase as a result of down-titration of the OCS dosage, in which case this would represent a corticosteroid-sensitive but relatively resistant eosinophilic asthma. A recent expert consensus statement relating to OCS use, tapering, adverse effects, adrenal insufficiency, and patient-physician shared decision-making has been published and will be helpful in the management of OCS therapy in severe asthma.

**Clinical Severe Asthma Phenotypes**

Clinicians over the years have described various descriptive phenotypes such as early childhood onset severe allergic asthma, late adult-onset eosinophilic asthma, obesity-associated asthma, aspirin-associated asthma, and smoking-associated asthma. In addition, clinical phenotyping has also been done on the basis of clinical features and the presence of chronic airflow obstruction and exacerbations. Unbiased methods of clustering used in the Severe Asthma Research Program have refined these clusters with identification of phenotypes of (1) early onset atopic asthma with mild to moderate severity, (2) obese late onset non-atopic asthma female patients with frequent exacerbations, and (3) those with severe airflow obstruction and use of daily OCS therapy. In the European Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes (U-BIOPRED) cohort that included severe smoking and ex-smoking patients, three severe asthma phenotypes were described: (1) late-onset asthma with past or current smoking and chronic airflow obstruction, (2) non-smoking severe asthma with chronic airflow obstruction and use of OCS therapy, and (3) obese female patients with frequent exacerbations but with normal lung function. Inclusion of sputum eosinophilia as a marker of eosinophilic asthma has resulted in two clusters: one of non-eosinophilic inflammation characterized by early-onset, symptom-predominant group in female obese patients, and another of eosinophilic inflammation with late-onset disease, associated with rhinosinusitis, aspirin sensitivity, and recurrent exacerbations, later described as a severe eosinophilic asthma phenotype [Supplementary Table 2, http://links.lww.com/CM9/A939].

**Molecular Phenotypes of Severe Asthma**

**Definition of T2-high phenotype**

The airway epithelium responds to external stimuli such as allergens, pollutants and infectious agents (eg, viruses) to cause the recruitment and/or activation of cells that are involved in the innate and adaptive immune response (such as dendritic cells, mast cells, and innate lymphoid cells), which leads to the orchestration of airway inflammation and mechanisms that drive the pathophysiology of asthma. Thus, it controls the regulation of T2 cytokines through the production of the alarmins such as thymic stromal lymphopoietin (TSLP), IL-25, and IL-33,
which can be induced following exposure of epithelial cells to external stimuli including environmental pollutants, viruses and allergens.[62] Figure 1. IL-33 is a member of the IL-1 cytokine family and an inducer of chemoattractants for T-helper type 2 cells (Th2). TSLP is an IL-7-related cytokine secreted by airway epithelial cells that activates dendritic cells to release chemokines that attract and activate Th2 cells. Expression levels of both IL-33 and TSLP are increased in airway epithelium of patients with asthma, particularly in those with severe asthma.[63,64] These alarmins can be produced in response to allergens such as house dust mite and A. fumigatus in a Toll-like receptor 4/myeloid differentiation factor 88 (MyD88)-dependent manner.[65,66] as well as exposure to diesel exhaust particles[67] and to virus infections.[68] There is also increased expression of the IL-33 and TSLP receptors in sputum cells from patients with severe asthma.[69]

The alarmins TSLP and IL-33 direct T-helper cells towards a Th2 phenotype with the secretion of IL-4, IL-5, and IL-13, and also directly stimulate innate lymphoid T2 cells to produce IL-5 and IL-13.[62] The Th2 cytokines, including IL-3, IL-4, IL-5, IL-9, and IL-13, are expressed in bronchial submucosa of patients with the disease. IL-5 is involved in the terminal differentiation of eosinophils and in the activation of airway eosinophils. IL-13 increases the activation of inducible nitric oxide synthase (iNOS) enzyme in the epithelium, leading to an increase in exhaled nitric oxide (NO), goblet cell metaplasia and bronchial hyperresponsive-ness. IL-4 promotes immunoglobulin E (IgE) synthesis and primes the vascular endothelium for the extravasation of eosinophils.

**T2-high and severe eosinophilic asthma**

Hierarchical clustering of differentially expressed genes between eosinophilic and non-eosinophilic inflammatory profiles using sputum cell transcriptomics revealed three molecular phenotypes.[70] The first transcriptomic-associated cluster (TAC1) was characterized by the immune receptors of IL-33, eotaxin (CC chemokine receptor 3), and TSLP with the highest enrichment of gene signatures.
for the IL-13/T2-inflammation signature being associated with sputum eosinophilia [Figure 2]. This grouped patients with severe asthma with OCS dependency, frequent exacerbations, and severe airflow obstruction, characteristics of the severe eosinophilic asthma phenotype[59] [Supplementary Table 2, http://links.lww.com/CM9/A939].

Using a different approach to determine the enrichment of an IL-13/T2-high gene expression signature in bronchial epithelial cells of patients with asthma, a T2-high phenotype was found in up to 37% of patients with severe asthma.[71] The T2-high patients were more symptomatic despite treatment with ICS and most often on OCS therapy, characterized by higher levels of nitric oxide in exhaled breath and of blood and sputum eosinophils. This, therefore, defined the molecular signature of the severe eosinophilic asthma. Using a composite measure of IL-4, IL-5, and IL-13 gene expression in induced sputum cells from severe asthma patients, 70% of patients on high dose ICS had a T2-high phenotype.[72]

The “T2-high” phenotype[70] is likely to be driven by activated eosinophils through the production of cytotoxic proteins such as major basic protein, eosinophil peroxidase, eosinophil cationic protein and eosinophil derived neurotoxin, which cause damage to epithelial and other lung structural cells.[73] Release of proinflammatory cytokines and chemokines and of lipid eicosanoid products may contribute to bronchial hyperresponsiveness and airway wall remodeling. The success of anti-IL5 and anti-IL5R antibody treatments in reducing exacerbations in severe eosinophilic asthma has firmed up this phenotype as an endotype while the therapeutic effects of anti-IgE antibody support the severe allergic asthma phenotype.

**Non-T2 pathways and neutrophilic asthma**

The second cluster, TAC2, derived from the U-BIOPRED sputum transcriptomic analysis was characterized by inflammasome-associated genes, interferon-α and tumor necrosis factor-α-associated genes, with sputum neutrophilia, high serum C-reactive protein levels and a higher prevalence of eczema, defining patients with neutrophilic asthma[69] [Figure 2]. The third phenotype (TAC3) was characterized by metabolic pathway genes, ubiquitination and mitochondrial function which are normally reduced in asthma and with paucigranulocytic inflammation and little airflow obstruction. The non-T2 pathways that could drive asthma pathobiology include type 1 innate lymphoid cells, inflammasome, neutrophil and IL-17 activation, oxidative phosphorylation, and interferon-gamma (IFNγ) activation.[74] Th1 CD4+ T cells produce IFNγ which plays a role in controlling intracellular infections and in autoimmunity. Th1 cells expressing IFNγ are increased in bronchoalveolar lavage fluid, sputum cells and bronchial biopsies from patients with asthma.[75-77] Bronchoalveolar lavage fluid from severe asthmatics patients showed greater Th1 cells and neutrophil numbers accompanied by higher IFNγ levels than in non-severe asthmatics.[78] Th17 cells are CD4+ T cells that express IL-17A, IL-17E, IL-17F, and IL-22 mediating neutrophil activation via IL-8 production.[79,80] Th17-associated cytokines IL-17A and IL-17F have been localized in the airways of patients with severe asthma.[81] Th17 cells have been implicated as a cause of neutrophilia in severe asthma.[82] An “IL-17-high” asthma phenotype has been characterized by bronchial epithelial dysfunction and upregulated antimicrobial and inflammatory response.[83] An IL-6 trans-signaling signature developed in U-BIOPRED also
indicated an IL-6 phenotype that drives non-T2 airway inflammation and epithelial dysfunction.\[84\]

Sputum neutrophilia has been associated with severe asthma, corticosteroid insensitivity, and chronic airflow obstruction\[85-88\] and is also observed during acute exacerbations\[89,90\]. Sputum neutrophilic inflammation associated with inflammasome activation supports the presence of a neutrophilic phenotype of asthma.\[70\] In neutrophilic asthma, an elevated gene expression of nucleotide-binding domain and leucine-rich, repeat-containing family, pyrin domain containing 3, caspase-1 and IL-18 in sputum cells has been reported.\[69,91\] Increased airway neutrophilia may be the result of infection, exposure to air pollutants, or treatment with corticosteroids, particularly OCSs.\[92\]

**Non-T2 pathways: airway wall remodeling**

Airway wall remodeling is characterized by an increase in airway smooth muscle mass, subepithelial fibrosis and increased numbers of mucous glands and goblet cells. The epithelium in severe asthma is thicker than in mild-moderate asthma, with increased proliferation, apoptosis and release of pro-inflammatory factors.\[93\] Airway smooth muscle mass increase is associated with airflow obstruction and bronchial hyper-responsiveness, with an enhanced proliferation rate.\[85,94,95\] Fibrocytes, which can differentiate into myofibroblasts, are increased in blood and in airway smooth muscle bundles in asthma patients with fixed airflow obstruction and/or severe disease.\[96-98\] Subepithelial thickening of the bronchial reticular layer is a feature of asthma of all severities.\[22,83,99\] Patients with severe asthma have increased expression of transforming growth factor-β isoforms and collagen deposition, compared to those with mild asthma, in association with eosinophilia.\[100,101\]

HRCT scan studies in asthmatic subjects may reveal abnormal radiologic findings, such as bronchial wall thickening, bronchial wall dilatation, bronchiectasis, mosaic lung attenuation, mucus plugging, prominent centriobular opacities, emphysema, and atelectasis.\[103,104\] Mosaic lung attenuation represents involvement of small airways (<2 mm) and acinar air spaces. Its delineation can be improved by using a expiratory phase computerized tomography (CT).\[105\] HRCT scan abnormalities such as bronchial wall thickening (62%), bronchial enlargement (40%), and emphysema (8%) have been shown to be present in 80% of severe asthma subjects.\[106\]

**Non-T2 pathways: corticosteroid insensitivity**

Severe asthma may be considered as having poor therapeutic response to corticosteroid therapy.\[107,108\] The defining feature of severe asthma is need for high dose ICS to gain disease control or despite this, the disease is poorly controlled (as previously described in this review), with only 62% of moderate to severe asthma gaining control with ICS and LABAs inhalers.\[109\] Corticosteroid insensitivity has been defined clinically by <15% improvement of peak expiratory flow rates from baseline after receiving 7 to 12 days of 30 mg of prednisolone.\[110\] Half of severe asthma patients in the U-BIOPRED cohort were on OCS therapy, and had a higher prevalence of nasal polyps, uncontrolled asthma, and a higher number of exacerbations compared with those not on OCS maintenance,\[111\] associated with elevated fractional exhaled nitric oxide (FeNO) and sputum eosinophils, evidence of corticosteroid insensitivity. After treatment with intramuscular triamcinolone, most patients showed little response in terms of lung function (FEV1), blood eosinophil count or levels of FeNO, accompanied by little change in the expression of IL-4, IL-5, and IL-13 genes in sputum cells, indicating a degree of corticosteroid insensitivity in this group.\[112\]

Cigarette smoking, bacterial infections, obesity, and deficiency of vitamin D have been associated with corticosteroid insensitivity.\[107,108\] Impaired nuclear translocation of the glucocorticoid receptor, activation of mitogen-activated protein kinase pathways, activation of transcription factors by IFNγ and increased oxidative stress resulting in reduction in histone deacetylase expression and activity are implicated molecular mechanisms.\[108\] The observations of overexpression of *Haemophilus parainfluenzae* (H. parainfluenzae) in bronchoalveolar lavage fluid and culture of *H. parainfluenzae* with macrophages inducing corticosteroid resistance in these cells link steroid resistance to *Haemophilus influenzae* infection.\[113\] Th17 cells may be induced by bacterial infections, and have been implicated in corticosteroid insensitivity.\[114,115\] The anti-IL5a antibody, mepolizumab\[116\] anti-IL-5Ra antibody, benralizumab,\[117\] and anti-IL-4Ra antibody, dupilumab\[53\] reduced maintenance dose of OCS by 50% in OCS-dependent patients with severe eosinophilic asthma, implicating a role for these T2 cytokines in corticosteroid insensitivity. Therefore, both T2 and non-T2 pathways may underlie corticosteroid insensitivity in severe asthma.

**Phenotyping and Biomarkers for Severe Asthma**

After the diagnosis of severe asthma has been ascertained, phenotyping in terms of whether the patient falls within the category of severe eosinophilic asthma should be determined [Figure 3]. This is often referred to as a T2 high phenotype asthma because the severe eosinophilic asthma has been linked to T2 inflammation as measured in the bronchial epithelium by the expression of genes involved in T2 inflammation.\[71\] Using this measure of T2 inflammation, a blood eosinophil count of 115 cells/mL was found to have the highest sensitivity and specificity for detecting T2 inflammation with a receptor operating curve discrimination of 68.9%.\[71\] The reason why this phenotype should be ascertained is that there are biologic treatments that target specific components of the type-2 inflammation (IL-5, IL-4, and IL-13) and provide clinical benefits when given to severe eosinophilic asthma patients.

Blood eosinophil count has been used to identify T2-high status, derived from the clinical trials of these biologic therapies. A level of 300 cells/mL blood eosinophil count...
has been used as the cut-off point although a level of > 150 cells/mL has also been used, with most studies showing that the higher the cut-off point used, the greater the beneficial effects of the biologic therapies (anti-IL5, anti-IL5Ra, and anti-IL4Ra antibodies) in terms of reduction in exacerbation rates. For anti-IgE therapy, a blood eosinophil count > 260/μL is predictive of this response in severe allergic patients.\[116\]

Sputum eosinophils are the most sensitive and specific noninvasive biomarker for eosinophilic airway inflammation,\[117\] but is difficult to obtain reliably and measure easily. A differential cell count of > 2% to 3% indicates an underlying eosinophilic inflammatory process and is diagnostic of eosinophilic airway disease.\[117\]

FeNO is another biomarker of T2 inflammation of the airways, indicating the activity of T2 cytokines IL-4 and IL-13, as these cytokines upregulate the expression of epithelial iNOS.\[118\] Recent evidence has confirmed the utility of using FeNO as an indicator of T2 inflammation, with its use as a tool for precision medicine in the management of severe asthma during periods of stability and instability.\[119\] The severe asthma ATS/ERS and Global Initiative for Asthma (GINA) guidelines have indicated that a FeNO > 20 parts per billion (ppb) is enough to indicate T2-high signal and to identify those who are likely to respond to current anti-T2 biologic therapies.\[120\]

**Therapeutic Approaches for Severe Asthma**

Once the patient with severe asthma has been phenotyped, consideration of therapeutic approaches remains the final important aim. Use of currently available controller treatments need to be ascertained irrespective of the phenotype of the asthma. Consideration needs to be given regarding new biologic therapies, particularly if the patient fulfills the criteria of a severe allergic or severe eosinophilic asthma, both being under the umbrella of T2-high inflammation.\[121\] (Figure 3). The list of currently available anti-T2 biologic therapies is shown in Figure 4. This represents the start of precision medicine for severe asthma.\[19,122\] There are currently no specific therapies for the various T2-low phenotypes, including neutrophilic asthma, airway wall remodeling and corticosteroid
insensitivity. However, long-term azithromycin and bronchial thermoplasty may be considered. Currently, anti-TSLP and anti-IL-33 antibody therapies are being developed which might target both T2-high and T2-low phenotypes.

Current Controller Treatments

Patients with severe asthma are by definition usually at steps 4 and 5 of the therapeutic recommendations of the GINA guidelines (https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf). Controller therapies using a combination of ICS and LABA remain the backbone of treatment, with the possibility of using the maximum dose of ICS, although the step-up of medium to high-dose ICS may only provide a small improvement in control. Nevertheless, a trial of high dose ICS is recommended with the proviso that if there is little benefit, maintenance ICS dose should revert to the medium dose. The more recent recommendation from GINA is on the use of the maintenance and reliever therapy approach using the single inhaler of formoterol and an ICS, for which there is support for its efficacy in reducing severe exacerbations.[123] Triple therapy of LABA-LAMA-ICS is now recommended for the treatment of severe asthma, with previous studies showing that the LAMA, tiotropium bromide, added to ICS-LABA inhalation improved lung function and reduced exacerbations compared to ICS-LABA alone.[124]

Biologic antibody therapies

Omalizumab

Omalizumab, the first approved biologic for asthma, is a recombinant humanized monoclonal antibody that binds to circulating free IgE, thereby preventing IgE binding to its receptor (FceR1) expressed on the surface of basophils and mast cells and therefore the release of mediators from these cells.[125] Omalizumab is indicated for severe allergic asthma in whom appropriate pharmacotherapy and allergy avoidance have not been helpful and in those with a total serum IgE from 30 to 700 IU/mL (with the possibility of including those with serum IgE levels up to 1300 IU/mL), and raised specific IgE to at least one aeroallergen.[11] A meta-analysis that included 3000 patients with moderate to severe asthma reported a decreased risk of exacerbation while ICS doses were successfully reduced during omalizumab treatment.[126] In a study of severe allergic asthma, omalizumab led to a 25% reduction in exacerbations while improving quality of life scores and asthma symptom scores.[127]

Treatment response should be evaluated at 4 months, using a combination of quality of life, exacerbation frequency and health care use. In a post hoc analysis of the EXACT study of omalizumab in subjects with moderate-to-severe persistent asthma, a high blood eosinophil count > 260 cells/mL and a FeNO > 19.5 ppb were found to predict those patients likely to benefit most with a reduction in exacerbation frequency.[117] However, in a prospective real-world study (PROSPERO study), these biomarkers had minimal predictive value for omalizumab treatment outcomes, particularly for exacerbation reduction,[128] questioning the need for using these biomarkers to predict responders.

Anti-IL-5/anti-IL-5Rα antibodies: mepolizumab, reslizumab, and benralizumab

Mepolizumab, reslizumab, and benralizumab block the IL-5 pathway which is the key cytokine for eosinophil maturation, survival and transition of this granulocyte from the bone marrow into the systemic circulation. Mepolizumab and reslizumab are immunoglobulin G (IgG) 4 humanized monoclonal antibodies that bind IL-5, thus preventing it from binding to the IL-5Rα on eosinophils.[121] On the other hand, benralizumab is an IgG1 humanized monoclonal antibody that targets the α subunit of the IL-5 receptor. It induces apoptosis of eosinophils and basophils through antibody-dependent cell mediated cytotoxicity.

These three monoclonal antibodies (mAbs) have been approved for use in patients with severe eosinophilic asthma that demonstrate a blood eosinophil count of ≥ 300 cells/µL and experience frequent exacerbations. They reduce the risk of exacerbations by 40% to 50% with modest effects on lung function,[129-132] which have been replicated in real-world practice.[133-135] Mepolizumab and benralizumab also reduced the maintenance dose of OCS in OCS-dependent patients with severe eosinophilic asthma by 50% while reducing the frequency of exacerbations.[131,132]

The 2019 GINA guidelines for severe asthma recommend the use of an anti-IL-5 and anti-IL-5Rα antibody for patients who remain uncontrolled with exacerbations in the past year despite step 4 or 5 therapy and who have a blood eosinophil count > 300 cells/µL (https://ginasthma.org/wp-content/uploads/2021/08/SA-Pocket-guide-v3.0-SCREEN-WMS.pdf). The ERS-ATS recommendation on
the other hand suggests a blood eosinophil count cut-off point ≥150 cells/μL.[119]

**Anti-IL4Rα antibody: dupilumab**

Dupilumab is a fully humanized monoclonal antibody directed at the α-subunit of the IL-4 receptor leading to the blockade of the effect of the T2-cytokines, IL-4, and IL-13.[121] involved in airway recruitment of eosinophils, B cell class switch to IgE production, goblet cell hyperplasia and mucus production, airway remodeling through airway smooth muscle proliferation and collagen deposition and airway epithelial cell expression of iNOS. Dupilumab decreased exacerbations in moderate to severe uncontrolled asthma, with greater improvements in those with higher blood eosinophil levels, reaching 67% in those patients with blood eosinophils ≥300 cells/μL.[116,117] The greatest treatment benefit in terms of reduction in exacerbation rates and improvement in FEV1 as compared with placebo was observed in patients with elevated T2 biomarkers (baseline blood eosinophil count of ≥150 cells/μL and baseline FeNO of > 25 ppb).[128] It is also effective in reducing OCS dose in those with severe OCS-dependent asthma while reducing exacerbation risk.[53]

Dupilumab therapy is also associated with improvements in lung function, asthma control and quality of life.

While the GINA severe asthma guidelines suggest using dupilumab for patients with severe eosinophilic asthma with exacerbations in the past year with either a blood eosinophil count of ≥150 cells/μL or a FeNO ≥25 ppb (https://ginasthma.org/wp-content/uploads/2021/08/SA-Pocket-guide-v3.0-SCREEN-WMS.pdf; checked on October 5, 2021), the ERS-ATS guidelines advise its use in severe eosinophilic asthma including corticosteroid-dependent asthma regardless of blood eosinophil counts.[119] However, those with higher blood eosinophil counts and higher FeNO are expected to respond better.

The indications for using these expensive biologic therapies are also dependent on the regulations set by the health care system of each country, which could be determined not only by being medically suitable for such therapies according to biomarker status, but also by other factors such as cost-benefit issues and affordability.

**Other Therapies for Severe Asthma**

**Bronchial thermoplasty**

Bronchial thermoplasty is a bronchoscopic procedure whereby intraluminal thermal energy is applied to the airway wall, with the aim of ablating the airway smooth muscle, although epithelial cells and nerves are also affected.[118] In patients with severe asthma, there is a modest effect in improving asthma-related quality of life scores and bringing some reduction in asthma exacerbations.[111] A sustained reduction in severe exacerbations over a 3-year follow-up period after bronchial thermoplasty in severe asthma with no improvement in pre- or post-bronchodilator FEV1 has been reported.[119] There is limited information on the identity of patients with severe asthma who will benefit most from bronchial thermoplasty. It has been suggested that bronchial thermoplasty should be considered for patients with severe asthma associated with non-T2 inflammation and non-eosinophilic inflammation. This procedure in patients with severe asthma resulted in 11.8% of 152 procedures associated with emergency respiratory readmission rates in 48.1% having a post-procedural stay in hospital.[140] A 10-year review of clinical data in patients that have undergone bronchial thermoplasty reported an increased rate of bronchiectasis.[141]

The Asthma guidelines of the Expert Panel Working Group of the National Heart Lung, and Blood Institute in the US have conditionally recommended against bronchial thermoplasty in individuals aged 18 years and older with persistent asthma.[142] It advised for the conduct of registered clinical trials and long-term registry studies of bronchial thermoplasty to fully assess the clinical benefits and harms.

**Long-term macrolide therapy**

An abnormal microbiome has been associated with severe asthma.[143] The use of antibiotics in the treatment of severe asthma is therefore of interest with a potential two-pronged mode of action using macrolide antibiotics as an antineutrophilic and an anti-bacterial agent. In a placebo-controlled study of patients with symptomatic asthma on ICS and LABA, azithromycin administered three times per week reduced the number of exacerbations (1.86 per patient year in the control group versus 1.07 in the active group) together with an improvement in asthma and quality of life.[144] It was not clear whether severe exacerbations or hospitalizations were reduced. Patients with eosinophilic asthma benefited as well as patients with non-eosinophilic asthma. Azithromycin reduced airway *H. influenzae* load, with no changes in total or pathogenic bacterial loads. But there is emergence of antimicrobial resistance. It is not known whether this therapy does improve outcomes among patients with severe asthma. The ERS-ATS severe asthma guidelines suggest a trial of macrolide treatment to reduce asthma exacerbations in adult asthma subjects on GINA/National Asthma Education and Prevention Program (NAEPP) step 5 therapy that remain persistently symptomatic or uncontrolled, but they suggest against the use of chronic macrolide treatment in children and adolescents with severe uncontrolled asthma.[119]

**Future directions**

The introduction of these T2 targeted biologic antibody treatments for severe asthma remains a big advance in the treatment of asthma. One particular area of therapeutic advance has been in reducing the need for OCS therapy in severe asthma by these biologic therapies. The current development of other biologics such as the anti-TSLP and the anti-IL-33 antibody represents further development as they block the effect of these alarmins, TSLP and IL-33, produced by epithelial cells interacting with environmental factors such as allergens, pollutants, and infectious agents. Patients with severe, uncontrolled asthma who received tezepelumab, a monoclonal antibody to TSLP,
had fewer exacerbations and better lung function, asthma control, and health-related quality of life than those who received placebo irrespective of the blood eosinophil counts.\(^{145}\) Thus, these may be targeting not only T2-mechanisms but also non-T2 mechanisms. Once these non-T2 pathways that may be driving severe asthma are defined, specific therapies can be developed to treat patients with non-T2 phenotype. The failure of some non-T2 targeted therapies such as anti-IL-17 or anti-tumor necrosis factor antibody treatments may have resulted from inadequate selection of asthma phenotype. Further advances will result from the application of precision medicine to severe asthma, which is bringing the right treatment to the right patient.\(^{145}\) The introduction of these efficacious treatments raises the issue as to whether these may represent disease modifying treatments, particularly if introduced earlier at the onset of severe asthma. Therefore, the best time to introduce these treatments for severe asthma with respect to the available treatments needs to be determined. The future looks very promising for severe asthma.

**Funding**

SG, JY and KFC are supported by the Sanming Project of Medicine in Shenzhen “Integrated Airways Disease Research Programme” (No. SZSM201612096). PD, HA-W, and PB, and KFC are supported by UK Research Innovation projects (No. MRC MR/T010371/1; EPSRC: EP/T003189/1).

**Conflicts of interest**

KFC has received honoraria for participating in Advisory Board meetings of GSK, AstraZeneca, Roche, Novartis, Merck, Boehringer Ingelheim, TEVA and Shionogi regarding treatments for asthma, chronic obstructive pulmonary disease and chronic cough and has also been remunerated for speaking engagements. PHP has received honoraria for participating in Advisory Board meetings of GSK and AstraZeneca, regarding treatments for asthma and has also been remunerated for speaking engagements. Other authors have no conflicts of interest to declare.

**References**

1. Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet 2019;394:407–418. doi: 10.1016/S0140-6736(19)31477-9.
2. Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015;135:896–902. doi: 10.1016/j.jaci.2014.08.042.
3. Backman H, Jansson SA, Stridsman C, Eriksson B, Hedman I, Eklund BM, et al. Severe asthma - a population study perspective. Exp Clin Allergy 2019;49:819–828. doi: 10.1111/ceaa.13378.
4. Su N, Lin JT, Wang WY, Chen P, Zhou X, Han HY, et al. A crosssectional study of severe asthma in eight provinces of China (in Chinese). Zhonghua Nei Ke Za Zhi 2016;55:917–921. doi: 10.3760/cma.j.issn.0026-6902.2016.12.002.
5. Wang WY, Lin JT, Zhou X, Chen P, Han HY, Yee KS, et al. A survey on clinical characteristics and risk factors of severe asthma in China (in Chinese). Zhonghua Yi Xue Za Zhi 2020;110:1106–1111. doi: 10.3760/cma.j.issn.122137-20191117-02497.
6. Wang G, Wang F, Gibson PG, Guo M, Zhang WJ, Gao F, et al. Severe and uncontrolled asthma in China: a cross-sectional survey from the Australasian Severe Asthma Network. J Thorac Dis 2017;9:1333–1344. doi: 10.21037/thd.2017.04.74.
7. Li XY, Hu N, Huang ZJ, Jiang Y, Wu F. Mortality and death cause proportion of respiratory disease in China, 2004–2005 (in Chinese). Zhonghua Yu Fang Yi Xue Za Zhi 2010;44:298–302. doi: 10.3760/cma.j.issn.0253-9624.2010.04.008.
8. Accordini S, Corsico AG, Braggion M, Gerbase MW, Gislason D, Gulsvik A, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 2013;160:93–101. doi: 10.1159/000338998.
9. Chung KF, Adcock IM. Precision medicine for the discovery of treatable mechanisms in severe asthma. Allergy 2017;74:1649–1659. doi: 10.1111/all.13771.
10. Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Blomme ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126:926–938. doi: 10.1016/j.jaci.2010.07.019.
11. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. European ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343–373. doi: 10.1183/09031984.00011614.
12. Chung KF, Diagnosis and management of severe asthma. Semin Respir Crit Care Med 2018;39:91–99. doi: 10.1055/a-0037-1607391.
13. Simpson AJ, Hekking PP, Shaw DE, Fleming LJ, Roberts G, Riley JH, et al. Treatable traits in the European U-BIOPRED adult asthma cohorts. Allergy 2017;74:406–411. doi: 10.1111/all.13629.
14. Tay TR, Lee J, Radhakrishna N, Hore-Lacy F, Stirling R, Hoy R, et al. A structured approach to specialist-referred difficult asthma patients improves control of comorbidities and enhances asthma outcomes. J Allergy Clin Immunol Pract 2017;5:956–964.e3. doi: 10.1016/j.jacip.2016.12.010.
15. Gibbons D, Heaney LG, Brightling CE, Niven R, Mansur AH, Chaudhuri R, et al. Dedicated severe asthma services improve health-care use and quality of life. Chest 2015;148:870–876. doi: 10.1378/chest.14-3056.
16. Lindsay JT, Heaney LG. Non-adherence in difficult asthma and advances in detection. Expert Rev Respir Med 2013;7:607–614. doi: 10.1586/17476438.2013.842129.
17. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF, Asthma and Allergy Research Group of the National Heart and Lung Institute. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003;22:478–483. doi: 10.1183/09031936.03.00017003.
18. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009;180:817–822. doi: 10.1164/rccm.200902-0166OC.
19. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF, et al. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003;22:478–483. doi: 10.1183/09031936.03.00017003.
20. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006;130:65–72S. doi: 10.1378/chest.130.1_suppl.65S.
21. Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/ National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2011;127:382–389. e1-13. doi: 10.1016/j.jaci.2010.11.015.
22. Wenzel SE, Schwartz LB, Langnach EL, Halliday JL, Trudeau JB, Gibbs RL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001–1008. doi: 10.1164/ajrccm.160.3.9812110.
23. Wenzel SE, Balzar S, Ampel PL, Haywicks GA, Buss W, Callouh WJ, et al. IL4R alpha mutations are associated with asthma exacerbations and mast cell/EGE expression. Am J Respir Crit Care Med 2007;175:570–576. doi: 10.1164/rccm.200607–906OC.
24. Haselkorn T, Fish JE, Zeiger RS, Szelfer SJ, Miller DP, Chippes BE, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The
76. Boniface S, Koscher V, Mamessier E, El Biaze M, Dupuy P, Lorec A, et al. Role of epithelial barrier dysfunction in the pathogenesis of asthma. Allergol Int 2018;67:12–17. doi: 10.1016/j.alli.2017.08.011.

75. Krug N, Madden J, Redington AE, Lackie P, Djukanovic R, et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 2010;184:4531–4537. doi: 10.4049/jimmunol.0903162.

74. Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, et al. Epithelial cell proliferation contributes to airway remodeling in severe asthma. J Allergy Clin Immunol 2013;132:1557–1563.e5. doi: 10.1016/j.jaci.2013.10.011.

73. Venge P, Dahl R, Fredens K, Peterson CG. Epithelial injury by human eosinophils. Am Rev Respir Dis 1988;138:554–557. doi: 10.1164/ajrccm.138.6.Pt_2.S54.

72. Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, et al. A transcriptome-driven analysis of epithelial abnormalities and bronchial biopsies to define asthma phenotypes in U-BIOPRED. Am J Respir Crit Care Med 2017;195:443–455. doi: 10.1164/rccm.201512-2432OC.

71. Krug N, Madden J, Redington AE, Lackie P, Djukanovic R, et al. T-cell epithelial phenotype evaluated at the single cell level in BAL and blood in allergic asthma. Am J Respir Cell Mol Biol 1996;14:319–326. doi: 10.1165/ajrccm.c14.8609033.

70. Boniface S, Koscher V, Mamessier E, El Biaze M, Dupuy P, Lorec A, et al. Assessment of T lymphocyte cytoxine GM-CSF in induced sputum from asthmatics: a flow cytometry study. Clin Exp Allergy 2003;33:1283–1243. doi: 10.1046/j.1365-2222.2003.01762.x.

69. Cho SH, Stanciu LA, Holgate ST, Johnston SL. Increased interleukin-1, interleukin-5, and interferon-gamma in airway CD4+ and CD8+ T cells in atopic asthma. Am J Respir Crit Care Med 2003;167:224–230. doi: 10.1164/rccm.200310-1416OC.

68. Raundhal M, Morse C, Khare A, Oriss TB, Milosevic J, Trudeu J, et al. High IFN-g and low SLPI mark severe asthma in mice and humans. J Clin Invest 2015;125:3037–3040. doi: 10.1172/jci80911.

67. Roussel L, Houle F, Chan C, Yao Y, Berube J, Olivenstein R, et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 2010;184:4531–4537. doi: 10.4049/jimmunol.0903162.

66. Halwani R, Al-Muhsen S, Hamid Q, T helper 17 cells in airway diseases: from laboratory bench to bedside. Chest 2013;143:494–501. doi: 10.1378/chest.12-0598.

65. Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, Rugman P, et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma. J Allergy Clin Immunol 2009;123:1185–1187. doi: 10.1016/j.jaci.2009.02.024.

64. Ostling J, van Geest M, Schofield JPR, Jevnikar Z, Wilson S, Ward J, et al. IL-17-high asthma with features of a psoriasis immunophenotype. J Allergy Clin Immunol 2014;134:1199–1213. doi: 10.1016/j.jaci.2013.09.027.

63. Jevnikar Z, Ostling J, Ax E, Calvelin J, Thoern K, Israelsson E, et al. Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. J Allergy Clin Immunol 2015;136:577–590. doi: 10.1016/j.jaci.2015.08.026.

62. Maceo P, Hew M, Torrego A, Jouneau S, Oates T, Durham A, et al. Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma. Clin Exp Allergy 2009;39:1668–1676. doi: 10.1111/j.1365-2222.2009.03319.x.

61. Jatakanon A, Ubas C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999;160:1532–1539. doi: 10.1164/ rccm.160.5.9806170.

60. Pavord ID, Brightling CE, Wollman G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999;355:2213–2214. doi: 10.1016/S0140-6736(99)91813-9.

59. Moore WC, Hart AT, Li X, Li H, Busse WW, Jarjour NN, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 2014;134:1557–1563.e5. doi: 10.1016/j.jaci.2013.10.011.

58. Fahy JV, Kim KW, Liu J, Boukley IA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995;95:843–852. doi: 10.1016/0091-6736(95)70128-1.

57. Quo R, Xie J, Chung KF, Li N, Yang Z, He M, et al. Asthma phenotypes defined from parameters obtained during recovery from a hospital-treated exacerbation. J Allergy Clin Immunol Pract 2018;6:1960–1967. doi: 10.1016/j.jcip.2018.02.012.

56. Simpson JL, Phipps WC, Barth KJ, Orme KM, Gunawardhana L, Gibson PG. Elevated expression of the NLPR3 inflammasome in neutrophilic asthma. Eur Respir J 2014;43:1067–1076. doi: 10.1183/09031936.00105013.

55. Nguyen LT, Lim S, Oates T, Chung KF. Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respir Med 2005;99:200–207. doi: 10.1016/j.rmed.2004.06.007.

54. Cohen L, TX, Tarsi J, Ramkumar T, Horiuchi TK, Cochran R, et al. Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med 2007;176:138–145. doi: 10.1164/rccm.200607-1062OC.

53. James AL, Bai TR, Massad T, Abramson MJ, Dolhnikoff M, McKay KO, et al. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. J Allergy Clin Immunol 2009;124:45–51.e1-4. doi: 10.1016/j.jaci.2009.03.049.

52. Saunders R, Siddiqui S, Kaur D, Doe C, Sutcliffe A, Hollins F, et al. Fibrobyte localization to the airway smooth muscle is a feature of asthma. J Allergy Clin Immunol 2009;123:376–384. doi: 10.1016/j.jaci.2008.10.048.
severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017;5:390–400. doi: 10.1016/s2213-2600 (17)30125-x.

133. Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J 2020;56:2000151. doi: 10.1183/13993003.00151-2020.

134. Kavanagh JE, Hearn AP, Dhariwal J, d’Ancona G, Douiri A, Roxas C, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest 2021;159:496–506. doi: 10.1016/j.chest.2020.08.2083.

135. Wechsler ME, Peters SP, Hill TD, Ariely R, DePietro MR, Driessen MT, et al. Clinical outcomes and health-care resource use associated with realizumab treatment in adults with severe eosinophilic asthma in real-world practice. Chest 2021;159:1734–1746. doi: 10.1016/j.chest.2020.11.060.

136. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018;378:2486–2496. doi: 10.1056/NEJMoa1804092.

137. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388:31–44. doi: 10.1016/S0140-6736(16)30307-5.

138. Pretolani M, Bergqvist A, Thabut G, Dombret MC, Knapp D, Hamidi F, et al. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathologic correlations. J Allergy Clin Immunol 2017;139:1176–1185. doi: 10.1016/j.jaci.2016.08.009.

139. Chupp G, Laviolette M, Cohn L, McEvoy C, Bansal S, Shifren A, et al. Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies. Eur Respir J 2017;50:1700017. doi: 10.1183/13993003.0017-2017.

140. Burn J, Sims AJ, Kelte K, Patrick H, Welham SA, Heaney LG, et al. Procedural and short-term safety of bronchial thermoplasty in clinical practice: evidence from a national registry and Hospital Episode Statistics. J Asthma 2017;54:872–879. doi: 10.1080/02770903.2016.1263632.

141. Chaudhuri R, Rubin A, Sumino K, Lapa ESJR, Niven R, Siddiqui S, et al. Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respir Med 2021;9:457–466. doi: 10.1016/s2213-2600(20)30408-2.

142. Cloutier MM, Baptiste AP, Blake KV, Brooks EG, Bryant-Stephens T, DiMango E, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020;146:1217–1270. doi: 10.1016/j.jaci.2020.10.003.

143. Chung KF. Airway microbial dysbiosis in asthmatic patients: a target for prevention and treatment? J Allergy Clin Immunol 2017;139:1071–1081. doi: 10.1016/j.jaci.2017.02.004.

144. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 2017;390:659–668. doi: 10.1016/s0140-6736(17)31281-3.

145. Menzies-Gow A, Corren J, Bourdon A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med 2021;384:1800–1809. doi: 10.1056/NEJMoa2034975.